Candel Therapeutics' CAN-2409 Receives European Orphan Designation for Pancreatic Cancer Treatment

Candel Therapeutics, Inc. announced the European Medicines Agency (EMA) has granted Orphan Designation to CAN-2409 for pancreatic cancer treatment, complementing its existing U.S. FDA Orphan Drug and Fast Track Designations. This recognition underscores the drug's potential to meet a critical need in treating this challenging disease. CAN-2409, an investigational therapy, works by inducing an immune response against solid tumors, including pancreatic ductal adenocarcinoma (PDAC), with promising survival benefits observed in clinical trials.

The EMA's Orphan Designation offers Candel Therapeutics benefits such as reduced regulatory fees and market exclusivity, facilitating the drug's development and potential availability in the EU. CAN-2409's mechanism involves transforming the tumor microenvironment to enhance immune response, a approach that has shown significant survival benefits in PDAC patients. With regulatory designations across multiple solid tumor indications, CAN-2409 represents a hopeful advancement in cancer immunotherapy.